Accéder au contenu
Merck
Toutes les photos(1)

Principaux documents

20030-U

Supelco

ORBO™ 502, gel de silice activée (20/45), 100/50 mg

W,W,F separators, O.D. × L 6 mm × 75 mm, pkg of 50 ea

Synonyme(s) :

Tube de silice activé ORBO™

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Code UNSPSC :
12190000
Nomenclature NACRES :
NB.24

Matériaux

W,W,F separators
silica gel

Niveau de qualité

100

Agence

NIOSH 2000,5518

Gamme de produits

ORBO™

Composition

Bed A, 100 mg
Bed B, 50 mg

Conditionnement

pkg of 50 ea

Fabricant/nom de marque

ORBO™ 502

Technique(s)

active air sampling: suitable

D.E. × L

6 mm × 75 mm

Matrice

activated silica gel

Taille des particules

20-45 mesh

Application(s)

air monitoring
environmental
industrial hygiene

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

ORBO 502 Activated Silica Gel (20/45) 100/50 mg sorbent tubes (W,W,F separators, O.D. × L 6 mm × 75 mm) contain two beds of the same selective adsorbent separated by glass wool or foam, for gas and vapor sampling. The dual-layer or two-bed construction of the tube allows for any sample breakthrough to be captured in the smaller back-up bed.

Informations légales

ORBO is a trademark of Sigma-Aldrich Co. LLC

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 3

1 of 3

Supelco

Supelco

20358

ORBO™ 90, Carboxen® 564 (20/45), 160/80 mg

ORBO-91 130/65 MG PK/25 W,W,W separators, O.D. × L 6 mm × 75 mm, pkg of 25 ea

Supelco

20360

ORBO-91 130/65 MG PK/25

ORBO™ 80 Isocyanate Filter with cassettes: no, filter O.D. 37 mm, pkg of 25 ea

Supelco

20811

ORBO™ 80 Isocyanate Filter

Bjørn T Moe et al.
Anticancer research, 29(4), 1047-1052 (2009-05-06)
Endometrial hyperplasia is a precursor lesion of endometrial carcinoma. Clinical studies of endometrial hyperplasia have shown that levonorgestrel (LNG) is more therapeutically effective than medroxyprogesterone acetate (MPA). The present pharmacological in vitro study was performed to compare progestin effects on
K Flo et al.
Scandinavian journal of clinical and laboratory investigation, 55(8), 715-721 (1995-12-01)
Elevated extracellular cGMP levels have been observed in various clinical conditions, and the analyte has been proposed as a diagnostic marker of cardiovascular as well as malignant diseases. However, the use of extracellular cGMP as a pathophysiological marker requires detailed
A Orbo et al.
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 117(7), 972-976 (1997-03-10)
The development of female steroid hormone-related neoplasms such as gynaecologic and mammary cancers is influenced by hormones administered exogenously. Hormonal contraceptives and hormone replacement therapy both affect the risk of developing cancers in the endometrium, cervix, ovarium, and mammary glands.
A Orbo et al.
Gynecologic oncology, 95(1), 82-88 (2004-09-24)
The purpose of the current study was to characterize the role of PTEN in malignant transformation and to evaluate the significance of mutated PTEN exons as prognostic markers in the carcinogenesis of endometrial hyperplasia. A comparison of PTEN mutations as
A Ørbo et al.
BJOG : an international journal of obstetrics and gynaecology, 123(9), 1512-1519 (2015-12-03)
To investigate relapse rates after the successful treatment of patients with non-atypical endometrial hyperplasia who were randomised to either a levonorgestrel-impregnated intrauterine system (LNG-IUS; Mirena(®) ) or two regimens of oral medroxyprogesterone acetate (MPA) after primary histological response. A multicentre
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique